Yesterday it was reported that a Director at Alkermes (ALKS), Paul Mitchell, exercised options to buy 7,000 ALKS shares at $8.98 a share, for a total transaction value of $62.86K.
Following this transaction Paul Mitchell’s holding in the company was increased by 87.5% to a total of $338.1K.
See today’s analyst top recommended stocks >>
Currently, Alkermes has an average volume of 1.2M.
Based on 8 analyst ratings, the analyst consensus is Hold with an average price target of $32.00, reflecting a 39.7% upside.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alkermes Plc IS a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include the brands Aristada and Vivitrol. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.
